Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358683
Status:
WITHDRAWN
Last Update Posted:
2012-05-28
First Post:
2006-07-28
Brief Title:
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohns Disease
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha TNF in Patients Suffering From Crohns Disease and Having Completed C87055 Study
Status:
WITHDRAWN
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary aim of this study is allow the patients suffering from Crohns disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment to receive treatment with certolizumab pegol until the drug is available for the Crohns disease indication in Greece
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RPCE06G0406 | None | None | None |